title: Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis.
abstract: OBJECTIVE
  Gastroparesis, a gastrointestinal autonomic neuropathy, is a common adverse reaction in chronic hepatitis C (CHC) patients receiving interferon therapy. Current therapeutic options are limited. We evaluated the efficacy of mosapride for IFN-induced gastroparesis.
  
  
  METHODS
  Twenty-four consecutive CHC patients were randomly assigned to either the control group, which received pegylated interferon α-2b at 1.5 μg/kg/week and ribavirin at 600-1,000 mg/day, depending on body weight (PegIFN/RBV), or the mosapride group, which received PegIFN/RBV plus mosapride at 15 mg/person/day. The solid-phase gastric emptying half-times (T1/2) of the total, proximal, and distal stomach (scintigraphy) and digestive symptoms (questionnaire) were measured within one week before and four weeks after initiation of the assigned therapy. The test meal comprised a 200-g pancake containing Tc-99m diethylenetriamine pentaacetic acid.
  
  
  RESULTS
  In the control group, after PegIFN/RBV initiation, a significant increase was observed in the total T1/2 (before: 84.0 ± 22.1 min versus after: 100.8 ± 28.9 min, P = 0.03), the distal T1/2 (before: 95.3 ± 32.2 min versus after: 115.3 ± 41.4 min, P = 0.03), and digestive symptom score (before: 3.2 ± 1.4 versus after: 8.1 ± 4.8, P = 0.02); proximal T1/2 change was not significant. In the mosapride group, no significant delays were observed in the total, proximal, and distal T1/2 values; the change in symptom scores was not significant.
  
  
  CONCLUSIONS
  Mosapride improved total and distal gastric motility in IFN-induced gastroparesis, and consequently relieved symptoms.
authors.affiliation: Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan. etsushi-k@med.osaka-cu.ac.jp
authors.forename: Etsushi
authors.initials: E
authors.lastname: Kawamura
authors.forename: Masaru
authors.initials: M
authors.lastname: Enomoto
authors.forename: Kohei
authors.initials: K
authors.lastname: Kotani
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hagihara
authors.forename: Hideki
authors.initials: H
authors.lastname: Fujii
authors.forename: Sawako
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Shuji
authors.initials: S
authors.lastname: Iwai
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Morikawa
authors.forename: Joji
authors.initials: J
authors.lastname: Kawabe
authors.forename: Kazunari
authors.initials: K
authors.lastname: Tominaga
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tamori
authors.forename: Susumu
authors.initials: S
authors.lastname: Shiomi
authors.forename: Norifumi
authors.initials: N
authors.lastname: Kawada
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005746:Gastric Emptying / Q000187:drug effects*; D018589:Gastroparesis / Q000139:chemically induced* / Q000503:physiopathology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012016:Reference Values; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009025:Morpholines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C062720:mosapride